Two studies recently projected the lifetime risk for RCC in individuals with PTEN mutations to be approximately 34%, although these were based on small numbers of cases and may be an overestimate reflecting ascertainment bias [30,31]. This evidence concerns the gene PTEN and renal cell carcinoma.